Aims: The use of beta-blocker therapy in cardiac amyloidosis (CA) is debated. We aimed at describing patterns of beta-blocker prescription through a nationwide survey. Methods and results: From 11 referral centres, we retrospectively collected data of CA patients with a first evaluation after 2016 (n = 642). Clinical characteristics at first and last evaluation were collected, with a focus on medical therapy. For patients in whom beta-blocker therapy was started, stopped, or continued between first and last evaluation, the main reason for beta-blocker management was requested. Median age of study population was 77 years; 81% were men. Arterial hypertension was found in 58% of patients, atrial fibrillation (AF) in 57%, and coronary artery disease in 16%. Left ventricular ejection fraction was preserved in 62% of cases, and 74% of patients had advanced diastolic dysfunction. Out of the 250 CA patients on beta-blockers at last evaluation, 215 (33%) were already taking this therapy at first evaluation, while 35 (5%) were started it, in both cases primarily because of high-rate AF. One-hundred-nineteen patients (19%) who were on beta-blocker at first evaluation had this therapy withdrawn, mainly because of intolerance in the presence of heart failure with advanced diastolic dysfunction. The remaining 273 patients (43%) had never received beta-blocker therapy. Beta-blockers usage was similar between CA aetiologies. Patients taking vs. not taking beta-blockers differed only for a greater prevalence of arterial hypertension, coronary artery disease, AF, and non-restrictive filling pattern (P < 0.01 for all) in the former group. Conclusions: Beta-blockers prescription is not infrequent in CA. Such therapy may be tolerated in the presence of co-morbidities for which beta-blockers are routinely used and in the absence of advanced diastolic dysfunction.

Tini, G., Cappelli, F., Biagini, E., Musumeci, B., Merlo, M., Crotti, L., et al. (2021). Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. ESC HEART FAILURE, 8(4), 3369-3374 [10.1002/ehf2.13411].

Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey

Crotti L.;Mariani D.;
2021

Abstract

Aims: The use of beta-blocker therapy in cardiac amyloidosis (CA) is debated. We aimed at describing patterns of beta-blocker prescription through a nationwide survey. Methods and results: From 11 referral centres, we retrospectively collected data of CA patients with a first evaluation after 2016 (n = 642). Clinical characteristics at first and last evaluation were collected, with a focus on medical therapy. For patients in whom beta-blocker therapy was started, stopped, or continued between first and last evaluation, the main reason for beta-blocker management was requested. Median age of study population was 77 years; 81% were men. Arterial hypertension was found in 58% of patients, atrial fibrillation (AF) in 57%, and coronary artery disease in 16%. Left ventricular ejection fraction was preserved in 62% of cases, and 74% of patients had advanced diastolic dysfunction. Out of the 250 CA patients on beta-blockers at last evaluation, 215 (33%) were already taking this therapy at first evaluation, while 35 (5%) were started it, in both cases primarily because of high-rate AF. One-hundred-nineteen patients (19%) who were on beta-blocker at first evaluation had this therapy withdrawn, mainly because of intolerance in the presence of heart failure with advanced diastolic dysfunction. The remaining 273 patients (43%) had never received beta-blocker therapy. Beta-blockers usage was similar between CA aetiologies. Patients taking vs. not taking beta-blockers differed only for a greater prevalence of arterial hypertension, coronary artery disease, AF, and non-restrictive filling pattern (P < 0.01 for all) in the former group. Conclusions: Beta-blockers prescription is not infrequent in CA. Such therapy may be tolerated in the presence of co-morbidities for which beta-blockers are routinely used and in the absence of advanced diastolic dysfunction.
Articolo in rivista - Articolo scientifico
Beta-blockers; Cardiac amyloidosis; Heart failure; Light chains; Transthyretin;
English
3369
3374
6
Tini, G., Cappelli, F., Biagini, E., Musumeci, B., Merlo, M., Crotti, L., et al. (2021). Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. ESC HEART FAILURE, 8(4), 3369-3374 [10.1002/ehf2.13411].
Tini, G; Cappelli, F; Biagini, E; Musumeci, B; Merlo, M; Crotti, L; Cameli, M; Di Bella, G; Cipriani, A; Marzo, F; Guerra, F; Forleo, C; Gagliardi, C; Zampieri, M; Carigi, S; Vianello, P; Mandoli, G; Ciliberti, G; Lichelli, L; Mariani, D; Porcari, A; Russo, D; Licordari, R; Ponziani, A; Porto, I; Perfetto, F; Autore, C; Rapezzi, C; Sinagra, G; Canepa, M
File in questo prodotto:
File Dimensione Formato  
Tini-2021-ESC Heart Fail-VoR.pdf

accesso aperto

Descrizione: Short communication
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 390.28 kB
Formato Adobe PDF
390.28 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/392933
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
Social impact